Actinogen Medical (ASX:ACW) EBIT per Share : A$-0.01 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical EBIT per Share?

Actinogen Medical's EBIT per Share for the six months ended in Dec. 2023 was A$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.01.

During the past 5 years, the average EBIT per Share Growth Rate was 12.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was 7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Actinogen Medical's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Actinogen Medical was 55.00% per year. The lowest was -48.10% per year. And the median was 13.80% per year.

ASX:ACW's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Actinogen Medical's EBIT for the six months ended in Dec. 2023 was A$-11.55 Mil.

Actinogen Medical EBIT per Share Historical Data

The historical data trend for Actinogen Medical's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical EBIT per Share Chart

Actinogen Medical Annual Data

Trend

Jun13

Jun14

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

EBIT per Share

Get a 7-Day Free Trial

-0.01

Actinogen Medical Semi-Annual Data
	Dec13	Jun14	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-0.01

Actinogen Medical EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Actinogen Medical's EBIT per Share for the fiscal year that ended in Jun. 2023 is calculated as

	EBIT per Share		(A: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-10.736	/	1875.607
=	-0.01

Actinogen Medical's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-11.546	/	2063.689
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.01

Actinogen Medical (ASX:ACW) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Actinogen Medical EBIT per Share Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinogen Medical (ASX:ACW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (ASX:ACW) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

3AC:Germany

Address

109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000

Website

https://www.actinogen.com.au

Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (ASX:ACW) Headlines

From GuruFocus

Stocks That Are Making A Good Come Back

By reports.droy reports.droy • 03-10-2015

Accuride Corporation: Earnings Report For Q2 2014

By Black Iguana Nitish • 10-13-2014